Dr. Reddy’s says FDA finds more issues at oncology drug plant

Breast Cancer Cells
Dr. Reddy's received a new FDA Form 483 for its cancer drug plant in India. (National Cancer Center)

The FDA continues to find issues with Dr. Reddy’s oncology formulation facility in Duvvada, India, one of three facilities earlier cited in a scathing warning letter. The Indian drugmaker said an inspection in September resulted in eight observations.

The acknowledgment (PDF) came in a press release to the Bombay Stock Exchange Tuesday, but it gave no details about the nature of the FDA’s concerns about the facility in Visakhapatnam. The statement said only that the company was addressing the observations.

The FDA in the 2015 warning letter raised a number of issues about the potential for contamination at the facility in the way that employees handled vials. A follow-up inspection in 2017 found more than a dozen issues, some of them repeats.

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

RELATED: Neopharma snatches Dr. Reddy's API business as it continues global expansion

Dr. Reddy’s has pending ANDAs for generic cancer drugs to be produced at the plant but has been prevented from launching any of them by the FDA citation. The stranglehold by the regulator has taken a toll on Dr. Reddy’s finances, and the Indian drugmaker has responded by selling off some assets and cutting costs.

The drugmaker in October sold its API manufacturing plant in Jeedimetla, Hyderabad to Therapiva, a joint venture of Abu Dhabi-based Neopharma and India’s Laxai Life Sciences, an emerging generics company. No terms were disclosed. In September,  Neopharma bought a 390,000-square-foot antibiotic manufacturing plant in Bristol, Tennessee.

Read more on

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.